Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease.

Diabetes Care
Gregory G SchwartzJohn Kittelson

Abstract

Incident type 2 diabetes is common among patients with recent acute coronary syndrome and is associated with an adverse prognosis. Some data suggest that cholesteryl ester transfer protein (CETP) inhibitors reduce incident type 2 diabetes. We compared the effect of treatment with the CETP inhibitor dalcetrapib or placebo on incident diabetes in patients with recent acute coronary syndrome. In the dal-OUTCOMES trial, 15,871 patients were randomly assigned to treatment with dalcetrapib 600 mg daily or placebo, beginning 4-12 weeks after an acute coronary syndrome. Absence of diabetes at baseline was based on medical history, no use of antihyperglycemic medication, and hemoglobin A1c and serum glucose levels below diagnostic thresholds. Among these patients, incident diabetes after randomization was defined by any diabetes-related adverse event, new use of antihyperglycemic medication, hemoglobin A1c ≥6.5%, or a combination of at least two measurements of serum glucose ≥7.0 mmol/L (fasting) or ≥11.1 mmol/L (random). At baseline, 10,645 patients (67% of the trial cohort) did not have diabetes. During a median follow-up of 30 months, incident diabetes was identified in 403 of 5,326 patients (7.6%) assigned to dalcetrapib and in 516 ...Continue Reading

References

Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
Dec 5, 2009·American Heart Journal·Gregory G SchwartzUNKNOWN dal-OUTCOMES Committees and Investigators
Mar 17, 2010·The New England Journal of Medicine·John J McMurrayRobert M Califf
Mar 25, 2011·The New England Journal of Medicine·Ralph A DeFronzoUNKNOWN ACT NOW Study
Apr 25, 2012·Current Diabetes Reports·Sanjum S SethiMichael E Farkouh
Aug 24, 2012·The New England Journal of Medicine·Lena M S CarlssonLars Sjöström
Nov 7, 2012·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN dal-OUTCOMES Investigators
Jan 11, 2013·Physiological Reviews·Josephine M Forbes, Mark E Cooper
Jun 7, 2014·Cardiovascular Research·Arnold von Eckardstein, Christian Widmann
Oct 15, 2014·Diabetes, Obesity & Metabolism·M A BethelM J Theodorakis
Jan 15, 2015·Circulation. Cardiovascular Genetics·Jean-Claude TardifMarie-Pierre Dubé
Apr 23, 2015·Circulation. Cardiovascular Quality and Outcomes·Suzanne V ArnoldMikhail Kosiborod
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Dec 17, 2015·Nature Reviews. Endocrinology·D John Betteridge, Rafael Carmena
Feb 18, 2016·The New England Journal of Medicine·Walter N KernanUNKNOWN IRIS Trial Investigators
Aug 4, 2016·JAMA Cardiology·Jon WhiteMichael V Holmes
Oct 5, 2016·JAMA : the Journal of the American Medical Association·Luca A LottaNicholas J Wareham
Jan 28, 2017·Arteriosclerosis, Thrombosis, and Vascular Biology·Jean-Claude TardifMarie-Pierre Dubé
May 18, 2017·The New England Journal of Medicine·A Michael LincoffUNKNOWN ACCELERATE Investigators
Aug 30, 2017·The New England Journal of Medicine·UNKNOWN HPS3/TIMI55–REVEAL Collaborative GroupMartin J Landray
Nov 8, 2018·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN ODYSSEY OUTCOMES Committees and Investigators

❮ Previous
Next ❯

Citations

Nov 25, 2020·Arteriosclerosis, Thrombosis, and Vascular Biology·Christian M MadsenBørge G Nordestgaard
Feb 17, 2021·Current Atherosclerosis Reports·Blake J CochranKerry-Anne Rye
Feb 20, 2021·Assay and Drug Development Technologies·Hermann A M Mucke
Mar 10, 2021·Current Atherosclerosis Reports·Muhammad Imtiaz Ahmad, Michael D Shapiro
Oct 21, 2020·Advanced Drug Delivery Reviews·Sumra NazirEmiel P C van der Vorst
May 1, 2021·Cells·Blake J CochranKerry-Anne Rye
May 1, 2021·International Journal of Molecular Sciences·Emilie W KjeldsenRuth Frikke-Schmidt
Jun 8, 2021·Circulation·Anand RohatgiKerry-Anne Rye

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02525939

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.

Related Papers

The New England Journal of Medicine
Gregory G SchwartzPhilip J Barter
The New England Journal of Medicine
Gregory G Schwartzdal-OUTCOMES Investigators
Clinical Pharmacokinetics
Donald M BlackTherese Heinonen
© 2021 Meta ULC. All rights reserved